Home › Therapeutic areas › Metabolic › Type 1 Diabetes
Type 1 Diabetes (9 companies)
Companies with an active program in Type 1 Diabetes.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 1 | Phase 1 | $304M | 9 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | 1 | Phase 2 | $212M | 3 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.60B | 15 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $647M | 12 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 1 | Phase 2 | $258M | 12 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.27B | 11 |
| SABS | SAB Biotherapeutics | Metabolic | 1 | Phase 2 | $273M | 1 |
| SANA | Sana Biotechnology | MetabolicOncology | 2 | Phase 1 | $710M | 4 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 2 | Phase 3 | $84.4M | 9 |
No companies match.